METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N-methyladenosine-dependent primary MicroRNA processing
Hepatology, ISSN: 1527-3350, Vol: 65, Issue: 2, Page: 529-543
2017
- 686Citations
- 190Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations686
- Citation Indexes686
- 686
- CrossRef631
- Captures190
- Readers190
- 190
- Mentions1
- News Mentions1
- News1
Most Recent News
m6A target microRNAs in serum for cancer detection
Abstract Recent studies have revealed the significant dysregulation of m6A level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a
Article Description
N-Methyladenosine (mA) modification has been implicated in many biological processes. However, its role in cancer has not been well studied. Here, we demonstrate that mA modifications are decreased in hepatocellular carcinoma, especially in metastatic hepatocellular carcinoma, and that methyltransferase-like 14 (METTL14) is the main factor involved in aberrant mA modification. Moreover, METTL14 down-regulation acts as an adverse prognosis factor for recurrence-free survival of hepatocellular carcinoma and is significantly associated with tumor metastasis in vitro and in vivo. We confirm that METTL14 interacts with the microprocessor protein DGCR8 and positively modulates the primary microRNA 126 process in an mA-dependent manner. Further experiments show that microRNA 126 inhibits the repressing effect of METTL14 in tumor metastasis. Conclusion: These studies reveal an important role of METTL14 in tumor metastasis and provide a fresh view on mA modification in tumor progression. (Hepatology 2017;65:529-543).
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85007376495&origin=inward; http://dx.doi.org/10.1002/hep.28885; http://www.ncbi.nlm.nih.gov/pubmed/27774652; https://journals.lww.com/01515467-201702000-00015; https://dx.doi.org/10.1002/hep.28885; https://journals.lww.com/hep/abstract/2017/02000/mettl14_suppresses_the_metastatic_potential_of.15.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know